论文部分内容阅读
目的探讨未足月胎膜早破孕妇(孕28～34周)产前应用盐酸氨溴索和地塞米松预防新生儿呼吸窘迫综合征的疗效。方法将100例未足月胎膜早破孕妇(孕28～34周)随机分为两组,即治疗组和对照组。治疗组:盐酸氨溴索1.0+5%GS500ml,静脉滴注,1次/d,3d,对照组:地塞米松5mg,肌内注射,每6h1次,8次。两组均为单疗程,观察两组新生儿呼吸窘迫综合征的发生率和新生儿病死率。结果发生新生儿呼吸窘迫综合征地塞米松组7例,发生率14%盐酸氨溴索组8例,发生率16%,两组比较差异无统计学意义(P>0.05),新生儿死亡各1例,均为28～30周之间。结论产前应用盐酸氨溴索能有效降低未足月胎膜早破早产儿呼吸窘迫综合征的发生率。
Objective To investigate the effect of prenatal application of ambroxol hydrochloride and dexamethasone on neonatal respiratory distress syndrome in pregnant women with preterm premature rupture of membranes (28-34 weeks of gestation). Methods 100 cases of premature rupture of membranes of pregnant women (gestational 28 to 34 weeks) were randomly divided into two groups, the treatment group and the control group. Treatment group: ambroxol hydrochloride 1.0 +5% GS500ml, intravenous infusion, 1 / d, 3d, control group: dexamethasone 5mg, intramuscular injection, every 6h1 times, 8 times. Both groups were single course of treatment. The incidence of neonatal respiratory distress syndrome and neonatal mortality in both groups were observed. Results 7 cases of neonatal respiratory distress syndrome dexamethasone group, the incidence rate of 14% ambroxol hydrochloride group in 8 cases, the incidence rate of 16%, no significant difference between the two groups (P> 0.05), neonatal deaths of 1 Cases, are between 28 to 30 weeks. Conclusion Prenatal ambroxol hydrochloride can effectively reduce the incidence of respiratory distress syndrome in premature infants without premature rupture of membranes.